Q3 FY2026 · ended Sep 30, 2026 · Revenue $209.25M, +11.4% YoY · Filed Oct 28, 2026
Neogenomics, Inc. (NEO) files with the SEC under industry code 8734, Services-Testing Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $209.3 million and a net loss of $7.5 million. Free cash flow was -$20.7 million. As of Sep 30, 2026 it held $139.3 million in cash and investments and $449.1 million in total debt.
Revenue
$209.25M
+11.4% vs year-ago quarter
Net income
$-7.55M
+72.2% vs year-ago quarter
Operating cash flow
$-8.88M
-200.0% vs year-ago quarter
Free cash flow
$-20.66M
-3724.2% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
129.39M
+0.0% vs year-ago quarter
Net cash
$-309.86M
Q3 FY2026
Operating margin
-6.3%
TTM
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- NEO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Fort Myers, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1077183
- Former names
- AMERICAN COMMUNICATIONS ENTERPRISES INC (until Feb 5, 2002)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- 20/20 Biolabs, Inc. AIDX
- Hypha Labs, Inc. FUNI
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $209.3M | $201.7M | $186.7M | $190.2M | $187.8M |
| Operating income | -$7.9M | -$9.8M | -$18.2M | -$13.4M | -$27.0M |
| Net income | -$7.5M | $2.2M | -$17.1M | -$9.9M | -$27.1M |
| Operating cash flow | -$8.9M | $20.0M | -$8.1M | $1.3M | $8.9M |
| Free cash flow | -$20.7M | $11.7M | -$13.1M | -$6.5M | $570,000 |
| Total assets | $1.4B | $1.4B | $1.3B | $1.4B | $1.4B |
| Total liabilities | $576.3M | $566.5M | $517.8M | $523.3M | $536.5M |
| Stockholders' equity | $800.6M | $785.7M | $828.8M | $836.6M | $838.3M |
| Cash and investments | $139.3M | $145.5M | $146.1M | $159.6M | $164.1M |
| Total debt | $449.1M | $448.4M | $66.3M | $409.5M | $68.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Bylaw or fiscal year change
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 11, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
All 1001 Neogenomics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.